Craig-Hallum raised the firm’s price target on GeneDx to $46 from $43 and keeps a Buy rating on the shares. The firm says it would be buying GeneDx following a substantial Q2 beat and raise as guidance still feels conservative and the company may be profitable sooner than expected.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS: